Abstract
TPS334Background: In recent years, the treatment of mCRPC has evolved and next-generation androgen receptor (AR)-axis targeting drugs (enzalutamide (ENZ), and abiraterone) have been approved and ar...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have